<DOC>
	<DOCNO>NCT01148953</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics single dose ALN-TTR01 patient transthyretin ( TTR ) mediate amyloidosis ( ATTR ) .</brief_summary>
	<brief_title>Trial Evaluate Safety Tolerability ALN-TTR01 Transthyretin ( TTR ) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Diagnosis TTR amyloidosis Adequate blood count , liver renal function Women childbearing potential must negative pregnancy test , breast feeding , must use adequate method birth control Males agree use appropriate contraception Willing able comply protocolrequired visit schedule visit requirement provide write informed consent . Known human immunodeficiency virus ( HIV ) positive status Receiving antibiotic bacterial infection within 7 day screen Known suspect systemic viral , parasitic fungal infection Receiving investigational agent within 30 day prior study drug administration Poor cardiac function Considered unfit study Principal Investigator Known sensitivity oligonucleotides Employee family member sponsor clinical study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>